Abstract
Proof of concept experiments have shown that tissue factor/factor VIIa inhibitors have antithrombotic activity without enhancing bleeding propensity. Starting from lead compounds generated by a biased combinatorial approach, phenylglycine amide tissue factor/factor VIIa inhibitors with low nanomolar affinity and good selectivity against other serine proteases of the coagulation cascade were designed, using the guidance of X-ray structural analysis and molecular modelling.
MeSH terms
-
Drug Design
-
Factor VIIa / antagonists & inhibitors*
-
Fibrinolytic Agents / chemical synthesis*
-
Fibrinolytic Agents / pharmacology
-
Glycine / analogs & derivatives*
-
Glycine / chemical synthesis*
-
Glycine / pharmacology*
-
Humans
-
Kinetics
-
Models, Molecular
-
Molecular Structure
-
Serine Proteinase Inhibitors / chemical synthesis
-
Structure-Activity Relationship
-
Thromboplastin / antagonists & inhibitors*
Substances
-
Fibrinolytic Agents
-
Serine Proteinase Inhibitors
-
phenylglycinamide
-
Thromboplastin
-
Factor VIIa
-
Glycine